DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Information source: Octapharma
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Immune Thrombocytopenic Purpura

Intervention: Octagam 10% (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Octapharma

Official(s) and/or principal investigator(s):
Wolfgang Frenzel, MD, Study Director, Affiliation: Octapharma


Octagam is a solvent/detergent-treated human normal immunoglobulin (IGIV) solution for intravenous administration. Octagam 5% is currently registered in about 80 countries. This study evaluated the efficacy and safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura (ITP) in adults. As Octagam 10% is essentially similar to Octagam 5%, it is expected that Octagam 10% is as efficacious and safe (in respect to viral safety) as Octagam 5%.

Clinical Details

Official title: Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of Participants With a Clinical Response

Secondary outcome:

Time to Achieve a Clinical Response

Maximum Platelet Count

Duration of the Clinical Response

Percentage of Participants With None, Minor, Mild, or Moderate Bleeding at Day 7

Detailed description: The primary objective of the study was to investigate the efficacy of Octagam® 10% in correcting platelet count. The blood count as well as laboratory chemistry were checked repeatedly up to day 21. The secondary objective of the study was to investigate the safety of Octagam® 10%. Safety was assessed by monitoring vital signs, evaluating adverse events, assessing laboratory parameters, and by viral safety testing.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Key Inclusion Criteria:

- Diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) according to standard


- Platelet count ≤ 20 x 10^9/L.

Key Exclusion Criteria:

- Chronic refractory ITP patients.

- Thrombocytopenia secondary to other diseases, or drug related thrombocytopenia.

- Administration of IGIV, anti-D, or other platelet enhancing drugs within 30 days

before enrollment.

- Administration of thrombocyte concentrates within 72 hours before baseline.

- Experimental treatment (eg, rituximab) within 3 months before enrollment.

- Prophylactic preoperative treatment for elective splenectomy.

- Severe liver or kidney disease.

- Pregnant or nursing female.

- History of hypersensitivity to blood or plasma derived products.

- Emergency operation.

- Live viral vaccination within the last month prior to study entry.

- Known IgA deficiency and antibodies against IgA.

Locations and Contacts

Contact Octapharma for information, Vienna, Austria
Additional Information

Starting date: June 2006
Last updated: July 28, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017